Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is conducted in Asia. The aim of this observational study is to evaluate current status of diabetes management, control and complications in diabetic subjects in Asia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| A |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No treatment given | Other | No treatment given |
|
| Measure | Description | Time Frame |
|---|---|---|
| Mean age of onset of type 1 and 2 diabetes mellitus | at baseline visit/study start | |
| Mean duration of treatment of type 2 DM | at baseline visit/study start | |
| Percentage of patients on Insulin and OAD therapy | at baseline visit/study start | |
| Mean duration of diabetes in type 1 and type 2 patients respectively | at baseline visit/study start | |
| Mean FPG and PPG of diabetic patients | at baseline visit/study start | |
| Mean HbA1c of diabetic patients | at baseline visit/study start | |
| Percentage of diabetic patients with HbA1c target below or equal to 7.0% | at baseline visit/study start | |
| Percentage of diabetic patients with HbA1c target below or equal to 6.5% | at baseline visit/study start | |
| Percentage of diabetic patients having dyslipidemia and hypertension | at baseline visit/study start | |
| Percentage of diabetic patients having cardiovascular complications | at baseline visit/study start |
| Measure | Description | Time Frame |
|---|---|---|
| Patients' perception will be analysed through Patient questionnaire measuring - Psychological well-being, Quality of life, Patients' compliant to treatment | at baseline visit/study start | |
| Physician perception of diabetes and its management will be analysed through Physician questionnaire measuring awareness about - HbA1c test and its goal, Anti-diabetic treatment, Barriers towards optimum diabetes control |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Patients with diabetes mellitus (both type 1 and type 2) being treated at general hospitals, diabetes clinics and referral clinics will be selected according to the inclusion and exclusion criteria.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Global Clinical Registry (GCR, 1452) | Novo Nordisk A/S | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Novo Nordisk Investigational Site | Singapore | 307684 | Singapore |
Not provided
| Label | URL |
|---|---|
| Clinical Trials at Novo Nordisk | View source |
Not provided
Not provided
| ID | Term |
|---|---|
| D003920 | Diabetes Mellitus |
| D003922 | Diabetes Mellitus, Type 1 |
| D003924 | Diabetes Mellitus, Type 2 |
| ID | Term |
|---|---|
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D004700 | Endocrine System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Blood sample
| Percentage of diabetic patients having peripheral vascular disease | at baseline visit/study start |
| Percentage of diabetic patients having diabetic nephropathy | at baseline visit/study start |
| Percentage of diabetic patients having diabetic eye complications | at baseline visit/study start |
| at baseline visit/study start |
| Duration of diabetes associated with highest number of diabetic complications | at baseline visit/study start |
| Minimum duration of diabetes associated with 10% incidence of diabetic complications (CVD, Nephropathy and retinopathy) | at baseline visit/study start |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |